A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis

• Published in: Journal of neuroimmunology Vol. 58; no. 1; pp. 1 - 10
• Main Authors: Kent, Sharon J., Karlik, Stephen J., Cannon, Catherine, Hines, Dawn K., Yednock, Ted A., Fritz, Lawrence C., Horner, Heidi C.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01-04-1995
• Subjects: Adhesion molecules; Experimental allergic encephalomyelitis; Treatment; VLA4; α4β1 integrin; α4β1 integrin; VLA4; Adhesion molecules; Treatment; Experimental allergic encephalomyelitis
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/0165-5728(94)00165-K

In experimental allergic encephalomyelitis (EAE), circulating leukocytes enter the central nervous system (CNS) producing inflammation, myelin damage and paralysis. Prevention of leukocyte infiltration by an antibody against α4 integrin suppressed clinical and pathological features of EAE in the guinea pig. Rapid clearance of leukocytes from the CNS and reversal of clinical findings were observed when anti-α4 treatment was administered during active disease. Clinical improvement was accompanied by a marked decrease in abnormal pathological findings, including demyelination. Therefore anti-α4 is an effective treatment of EAE and may be similarly useful in the treatment of autoimmune diseases such as multiple sclerosis.